Investigational Drug Information for Motexafin gadolinium
✉ Email this page to a colleague
What is the drug development status for Motexafin gadolinium?
Motexafin gadolinium is an investigational drug.
There have been 35 clinical trials for Motexafin gadolinium.
The most recent clinical trial was a Phase 3 trial.
The most common disease conditions in clinical trials are Lung Neoplasms, Glioblastoma, and Central Nervous System Neoplasms. The leading clinical trial sponsors are Pharmacyclics LLC., National Cancer Institute (NCI), and Northwestern University.
Summary for Motexafin gadolinium
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,937 |
| WIPO Patent Applications | 1,178 |
| Japanese Patent Applications | 572 |
| Clinical Trial Progress | Phase 3 (1969-12-31) |
| Vendors | 14 |
Recent Clinical Trials for Motexafin gadolinium
| Title | Sponsor | Phase |
|---|---|---|
| Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy | National Cancer Institute (NCI) | N/A |
| Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy | American College of Radiology Imaging Network | N/A |
| Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL | Pharmacyclics LLC. | Early Phase 1 |
Clinical Trial Summary for Motexafin gadolinium
Top disease conditions for Motexafin gadolinium
Top clinical trial sponsors for Motexafin gadolinium
US Patents for Motexafin gadolinium
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
